Presentations

      Innovation of Reduced Risk Alternatives: Oral Tobacco and Nicotine Products

      Gunduz, N.

      Conference date
      Jun 21, 2023
      Conference name
      Global Forum on Nicotine 2023
      Link to more information
      Topic
      Summary

      Recent technological developments of new smoke-free products such as heated tobacco products, e-vapor products, and oral nicotine pouches that have the potential to provide nicotine with fewer and lower levels of harmful chemicals compared with combustible products like cigarettes have made it possible to offer a portfolio of smoke-free products to adult smokers who would otherwise continue to smoke as alternatives to cigarettes and other combusted products.

      Nicotine pouches are a relatively new addition to the market of oral nicotine products and have been present on the U.S. market since 2016 and in Europe since 2018. These pouches are similar to snus but do not contain tobacco. Instead, nicotine pouches contain tobacco-derived or synthetic nicotine, flavorings, and other ingredients.

      The scientific assessment of oral products, like nicotine pouches, that substantiates the reduced-risk potential includes characterization of the chemical composition of the product, pre-clinical and clinical toxicological assessments, and product use characterization.

      In this presentation we discuss the low-risk potential of nicotine pouches and their place in the risk continuum of tobacco and nicotine-containing products.

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
      ​
      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.